WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off. : 6-9 & 10, Laxmi Towers, L.S.C., Block C, Saraswati Vihar, Delhi -1 10034.

Phone : 2701 1428 Fax : 27023256

CIN No. L24232DL1996PLC227773

25.04.201 6
THE STOCK EXCHANGE MLlMBAl
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001
File No: 524661
Sub: Regulation 33 of the SEBl Listing Requlations
Dear Sir,
We are hereunder furnishing the audited financial results for the quarter ended 31.03.16 as reviewed by the Audit
Committee & approved by Board of Directors in their respective meetings held on 25.04.2016.
(Figures i n Lacs)
Pr. F.Y.E. On
Particulars
Qtr. Ended on
Year to Date
31.03.16
31.03.2016
31.03.15
1. lncome from Operations

(a) Net Sales1 lncome from operations(net of excise duty)

(b) Other Operating Income
Total Income from o~erations(net)
2.Expenses
(a)Cost of Raw Material Consumed
(b)Purchase of Stock in trade
(c)Changes in inventories of finished goods, work-inprogress and stock in trade
(d)Employee benefit expenses
(e) Depreciation and amortization expense
(9 Other expenses
Total E x ~ e n s e s
3. Profit/(Loss) from Operations before other Income.
I
Finance costs & ~xcebtionalItems(1-2)
4.0ther Income
5.Profit/(Loss) from ordinary activities Finance costs &
Exceptional ltems
6. Finance Costs
7. Profit/(Loss) from ordinary activities after finance
costs but before Exceptional ltems
8. Exceptional ltems
9. Profit/(Loss) from ordinary activities before tax
10. Tax Ex~ense
11. Net Profit/(Loss) from ordinary activities after tax
12. Extra-ordinary item
13. Net Profit I(Loss) for the period
14. Share of Profit/(loss) of associates
15. Minority Interest
16. Net profit/(Loss) after taxes, minority interest and
share of profit/(loss) of associates
17. Paid up Equity Share Capital(Face value of the
share- Rs.10)
18. Reserves excluding Revaluation Reserves as per

3.66
3.66

9.99
9.99

5.07
5.07
0
0
0

1.10
1.10
2.56

6.75
6.75
3.24

0
0
4.72
4.72
(0.35)
.
.

5.16
7.72

5.31
8.55

0.24
0.59

7.72

8.55

0.59

7.72

8.55

0.59

7.72

8.55

0.59

7.72

8.55

0.59

7.72

8.55

0.59

1212.00

1212.00

1212.00

(1212.10)

(1210.69)

(1219.24)

0.06
0.06

0.07
0.07

0.06
0.06

0.07
0.07

9
19.i Earning Per Share (before extraordinary items) (of
Rs.101-each)(not annualized)
(a) Basic
(b) Diluted
19.ii Earning Per Share (after extraordinary items) (of
Rs.101-each)(not annualized)
(a) Basic
(b) Diluted

Statement of Assets and liabilities for the year ended 31.03.2016

As reviewed by the Audit Committee, following statement of assets and liabilities were approved and taken note by
the Board of Directors:
(figures i n Rs. Lacs)
I As at Previous Year
Statement of Assets and liabilities
I As at Year ended
ended (31.03.201 5)
(31.03.2016)
Particulars
Audited
Audited

1 Shareholders' funds
(a) Share Capital

1,211.85

1,211.85

I
I

(b) Reserves and Surplus

( c) Money received against share warrants
1.16

Sub-total-shareholder's funds
2. Share application money pending
allotment
3. Minority Interest
4. Non-current liabilities
(a) Long Term borrowings
(b) Defererd Tax liabilities(net)

1
1

I
I

(c) Other long term liabilities

(d) Long trem provisions

I
I

Sub-total- Non Current liabilities

5. Current liabilities
(a) Short trem borrowings
(b) Trade Payables

0.40

(c) other current liabilities

Total

1.56

Non Current assets

Current assets
(a) Inventories
-

(c) Cash and Bank balances

5.43
0.53

0.53
1.03

(d) Other current assets

(e) Short term loans and advances
Total

1.56

5.96

Thanking you,
for Welcure Drugs & Pharmaceuticals Ltd.

Sudhir Chandra
Managing Director

WM

1VI.L. Bhateja
CFO

Rashi Aggarwal
Company Secretary